Clinical trials: HPV Cancers
Papillomavirus Infections
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India.
- Trial name
- NCT00380367
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus
Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IIb study is designed to evaluate the the long-term efficacy, safety and immunogenicity of the 580299 HPV…
- Trial name
- NCT00518336
- Testing
- Blood sampling, Collection of cervical specimen, Cervarix
- Where
- 5 sites in Brazil
- Volunteers
- 433 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Papillomavirus Infections, Health Behavior
Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination
This is a minimal risk, anonymous, convenience sample, social behavioral study using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding…
- Conditions
- Papillomavirus Infections, Health Behavior, Attitude of Health Personnel, Human Papilloma Virus, Male
- Trial name
- NCT02897232
- Testing
- Survey
- Where
- United States
- Volunteers
- 386 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Oropharyngeal Cancer
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
This is a single-center phase 2 study of to test how well the combination of toripalimab with chemotherapy followed by TORS or risk and response stratified de-escalated (chemo)radiotherapy works in patients with in HPV16+…
- Trial name
- NCT07290621
- Testing
- Toripalimab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Cervical Cancer, Human Papilloma Virus
HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV
Our study will assess and measure population effectiveness of prophylactic HPV vaccine in reducing cervical, anal, and/or oral prevalent and 6-month persistent infections among HPV-vaccinated and 757 HPV-unvaccinated Rwandan WLWH…
- Conditions
- Cervical Cancer, Human Papilloma Virus, Human Immunodeficiency Virus, HPV-Related Carcinoma
- Trial name
- NCT05247853
- Testing
- Blood collection, Oral, cervicovaginal and anal specimen collection, Anoscopy & Biopsy of Acetowhite Lesions
- Where
- Rwanda
- Volunteers
- 3,127 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Genital Warts
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
The purpose of this study is to compare the recurrence rate following total clearance of external genital warts (EGWs) when clearance has been obtained by imiquimod (3 applications per week for 4 weeks) followed by ablative…
- Trial name
- NCT00189293
- Testing
- Imiquimod, vehicle cream
- Where
- 12 sites in Italy
- Volunteers
- 128 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Uterine Cervical Neoplasm
Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples
The purpose of the study is to compare the results of the Becton Dickinson (BD) Human Papilloma Virus (HPV) Assay on the Viper LT instrument from Liquid-based cytology media diluted in HPV diluent to adjudicated histology results…
- Trial name
- NCT03020121
- Testing
- Colposcopy/biopsy
- Where
- 12 sites in United States, Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Becton, Dickinson and Company
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-303 is a prospective, randomized, double-blind, placebo-controlled study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- NCT03721978
- Testing
- VGX-3100, CELLECTRA™-5PSP
- Where
- 53 sites in United States, Argentina and 8 more
- Volunteers
- 203 people
- Sponsor
- Inovio Pharmaceuticals
Infections, Papillomavirus
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 580299/008 and received the control vaccine (Hepatitis A vaccine).
- Trial name
- NCT00799825
- Testing
- GSK Biological's HPV vaccine GSK580299 (Cervarix™)
- Where
- 48 sites in United States, Canada
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nasopharyngeal Carcinoma
The Prognostic Value of Human Papilloma Virus in Nasopharyngeal Carcinoma
It is well established that HPV infection has a casual and is a prognostic factor in several cancer types, including oropharynx. We wish to examine if HPV infection has a prognostic significance in nasopharyngeal carcinoma.
- Trial name
- NCT04014738
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Rambam Health Care Campus
Malignant Tumor of Cervix, Cervical Intraepithelial Neoplasia
Participation in Screening for Cervical Cancer: Interest of a Self-sampling Device Provided by the General Practitioner
This study evaluates the benefit in women aged from 30 to 65 years, who do not participate to the French opportunistic cervical cancer screening program, of an organized screening with the proposition by the family physician of a…
- Trial name
- PaCUDAHL-Gé (NCT02749110)
- Testing
- Vaginal self-sampling brush
- Where
- France
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
HPV Infection
Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial
A 3-dose HPV vaccination scheme has shown to be safe and immunogenic in people living with HIV (PLWH), although evidence on 1-dose, which is important to improve coverage, is scarce.
- Trial name
- H2VICTORY (NCT05173324)
- Testing
- HPV vaccine, HPV testing, HAV vaccine
- Volunteers
- 8,000 people
- Sponsor
- International Agency for Research on Cancer
HPV Infection, Cervical Cancers
Remote Resilience: Novel Applications of mHealth in Nicaragua's Cancer Control Program
The goal of this clinical trial is to test an mHealth intervention for cervical cancer prevention in under-screened women ages 25-64 on the Caribbean Coast of Nicaragua.
- Trial name
- NCT06921798
- Testing
- mHealth
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Virginia
HPV
Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment
The occurance and clinical course of human papillomavirus (HPV)-induced lesions is largely determined by the nature of the cellular immune defense generated.
- Trial name
- NCT00941811
- Testing
- Imiquimod
- Where
- Austria
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Cervical Cancer Screening
HPV Self-Sampling for Cervical Cancer Screening Among Lesbian, Bisexual, and Queer (LBQ) Women
The proposed study will examine the implementation of a Human Papilloma Virus (HPV) self-sampling intervention for under screened LBQ women living in South Florida.
- Trial name
- NCT03012932
- Testing
- HPV self-sampling
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Miami
Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)
Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
This phase I research protocol is designed to assess immunogenicity and clinical endpoints in patients with human papillomavirus (HPV) 16 cervical intraepithelial neoplasia (CIN)2/3.
- Trial name
- NCT02354534
- Testing
- Artesunate Suppositories
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Uterine Cervical Neoplasm
HPV Self-sampling for Underscreened Latinas
The goal of this study is to learn if women of Hispanic/Latina ethnicity are willing to self-collect a cervico-vaginal sample for HPV testing.
- Trial name
- NCT06439706
- Testing
- HPV Self-Sampling, Group Education
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Uterine Cervical Neoplasm, Uterine Neoplasm
Offering Cervical Cancer Screening to Older Women
This study evaluates the effect and feasibility of expanding the target population in the Danish cervical cancer screening program to include women aged 65 to 69 years.
- Conditions
- Uterine Cervical Neoplasm, Uterine Neoplasm, Uterine Cervical Disease, Mass Screening
- Trial name
- NCT04114968
- Testing
- GP-based screening or HPV self-sampling
- Where
- Denmark
- Volunteers
- 20,000 people
- Sponsor
- University of Aarhus
Cervical Cancer, Cervical Dysplasia
Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study
In Singapore, the current cervical cancer screening uptake among women in Singapore has remained at low 50% since its introduction in 2004.
- Conditions
- Cervical Cancer, Cervical Dysplasia, Human Papillomavirus Infection
- Trial name
- NCT03813576
- Testing
- Self-collected HPV vaginal swab
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
ASC-US, Human Papilloma Virus
Can B12 and Folate Levels Predict HPV Penetration in Patients With ASCUS?
Non-classified atypical squamous cells (ASCUS) is the most common abnormal cervical cytology (%39). The risk of cervical intraepithelial neoplasia 2-3 is 5% and the risk of carcinoma is around 0.1% after diagnosis.
- Trial name
- NCT03903952
- Testing
- Vitamin B12 and folate
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sanliurfa Mehmet Akif Inan Education and Research Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.